T. Rowe Price Associates
LUCD icon

T. Rowe Price Associates’s Lucid Diagnostics LUCD Stock Holding History

T. Rowe Price Associates’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Buy
121,952
+47,575
+64% +$51.3K ﹤0.01% 3106
2026
Q1 		$86K Buy
74,377
+39,241
+112% +$49.9K ﹤0.01% 3025
2025
Q4 		$39K Hold
35,136
– – ﹤0.01% 3059
2025
Q3 		$36K Hold
35,136
– – ﹤0.01% 3023
2025
Q2 		$41K Buy
+35,136
New +$45.4K ﹤0.01% 3021

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

T. Rowe Price Associates's LUCD Position: Q2 2026 in Review

T. Rowe Price Associates increased its Lucid Diagnostics (LUCD) stake by 64% in Q2 2026, buying an estimated $51.3K and bringing the position to 121,952 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #3106.

T. Rowe Price Associates first reported a position in LUCD in Q2 2025 and has held it in 5 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • T. Rowe Price Associates held 121,952 shares of Lucid Diagnostics worth $131K as of Q2 2026.
  • T. Rowe Price Associates bought 47,575 Lucid Diagnostics shares in Q2 2026, an estimated $51.3K.
  • Lucid Diagnostics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3106 holding.
  • T. Rowe Price Associates first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.